ONWARD Medical, a medical technology company creating spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces the successful first-in-human implant of its ARC-IM Stimulator, to restore upper extremity function after SCI. The patient also received a wireless brain-computer interface (BCI), designed to initiate thought-driven movement when paired with ARC-IM.
ONWARD ARC-IM delivers targeted, programmed ARC-IM Therapy to the spinal cord to restore movement and other functions after spinal cord injury. ARC-IM Therapy has been applied across multiple clinical feasibility studies to restore mobility and stabilize blood pressure after SCI. For the first time, ARC-IM Therapy has now also been used to restore upper extremity movement and function.
Two procedures were performed last month by neurosurgeon Jocelyne Bloch, MD, at Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne, Switzerland. The ARC-IM implant procedure took place on August 14, 2023, and nine days later the BCI WIMAGINE from CEA-Clinatec was implanted.
Working in concert with ARC-IM, the BCI is engineered to capture the intention of a paralyzed individual to move their upper extremities and uses artificial intelligence to decode those thoughts. ARC-IM then converts the decoded information into ARC-IM Therapy - precise stimulation of the spinal cord - resulting in thought-driven movement.
“The implant procedures involving the ONWARD ARC-IM and Clinatec BCI went smoothly,” said Dr. Jocelyne Bloch. “We are now working with the patient to use this cutting-edge innovation to recover movement of his arms, hands, and fingers. We look forward to sharing more information in due course.”
This latest breakthrough is part of an ongoing clinical study investigating the safety and effectiveness of thought-initiated spinal cord stimulation after SCI. It builds on the ONWARD announcement from May 2023 that pairing its ARC Therapy with a BCI implant resulted in an individual gaining augmented control over movement of his paralyzed legs. The study is supported by a grant from the European Innovation Council (Reverse Paralysis project) and is coordinated by .NeuroRestore co-Directors – Professor Grégoire Courtine and Dr. Jocelyne Bloch – as well as Guillaume Charvet, head of the Medical Device Development Lab at CEA-Clinatec.
“This is another impressive piece of research from our partners at .NeuroRestore. We are excited to learn how ARC-IM Therapy may restore upper extremity function after SCI, and we are eager to see how the addition of a BCI might augment our therapy,” said Dave Marver, CEO of ONWARD. “Congratulations to the teams at EPFL, CHUV, and CEA-Clinatec for this breakthrough. We feel privileged that our technology is part of this research.”
The Company expects to share more information about this pioneering research in the coming months, concurrent with a peer-reviewed publication describing the procedure and results.